![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() | GDUFA II Training - Performance Goals, Vince Sansone (U.S. Food and Drug Administration) View |
![]() | GDUFA II Training IR and DR Letters, Michael Folkendt (U.S. Food and Drug Administration) View |
![]() | GDUFA II – Review Timelines (14of27) Generic Drugs Forum 2018 (U.S. Food and Drug Administration) View |
![]() | GDUFA II (9/28) Generic Drugs Forum 2017 (U.S. Food and Drug Administration) View |
![]() | GDUFA (U.S. Food and Drug Administration) View |
![]() | Drug Master Files from a GDUFA II User Fee Perspective (U.S. Food and Drug Administration) View |
![]() | What’s New in the Inactive Ingredient Database (IID) (U.S. Food and Drug Administration) View |
![]() | GDUFA II Training - Post Complete Response Letter Meeting Request, Anh Bui (U.S. Food and Drug Administration) View |
![]() | Dr. Hahn's Remarks to “Advancing Innovative Science in Generic Drug Development” Workshop 9/29/2020 (U.S. Food and Drug Administration) View |
![]() | Controlled Correspondence Related to Pharmaceutical Quality (U.S. Food and Drug Administration) View |